325 related articles for article (PubMed ID: 25375891)
1. Role of tumour angiogenesis in haematological malignancies.
Medinger M; Passweg J
Swiss Med Wkly; 2014; 144():w14050. PubMed ID: 25375891
[TBL] [Abstract][Full Text] [Related]
2. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
4. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenesis in haematological malignancies.
Li WW; Hutnik M; Gehr G
Br J Haematol; 2008 Dec; 143(5):622-31. PubMed ID: 19036013
[TBL] [Abstract][Full Text] [Related]
6. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.
Negaard HF; Iversen N; Bowitz-Lothe IM; Sandset PM; Steinsvik B; Ostenstad B; Iversen PO
Leukemia; 2009 Jan; 23(1):162-9. PubMed ID: 18800145
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis and hematological malignancies].
Iversen PO
Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3198-200. PubMed ID: 14714007
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and its receptors in multiple myeloma.
Ria R; Roccaro AM; Merchionne F; Vacca A; Dammacco F; Ribatti D
Leukemia; 2003 Oct; 17(10):1961-6. PubMed ID: 14513045
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.
Bolkun L; Lemancewicz D; Sobolewski K; Mantur M; Semeniuk J; Kulczynska A; Kloczko J; Dzieciol J
Adv Med Sci; 2013; 58(1):118-25. PubMed ID: 23333895
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of angiogenesis inhibitors in hematologic malignancies.
Giles FJ
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in multiple myeloma.
Vacca A; Ria R; Reale A; Ribatti D
Chem Immunol Allergy; 2014; 99():180-96. PubMed ID: 24217610
[TBL] [Abstract][Full Text] [Related]
14. New Insights in Anti-Angiogenesis in Multiple Myeloma.
Ribatti D; Vacca A
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
16. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
17. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]